You are here
Arrayit Corporation Signs Allergy Testing Contracts with a Nationwide Consortium of Medical Clinics
Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of medical clinics nationwide. The network comprises 178 medical clinics in 29 of the 48 contiguous United States including the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions, with single clinics staffing up to 70 physicians. The clinics are using Arrayit allergy testing services to assist physicians in diagnosing and treating allergy and asthma across a wide range of medical specialties and focus areas including anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women’s health.
Arrayit recently established a nationwide sales network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests to medical clinics and retail chains, completed allergy pilot testing with one the nation’s largest chains of retail stores, met with top officials at the United States Food and Drug Administration (FDA) to discuss FDA approval of a major product line, and reported the sale of clinical instrumentation to the FDA. Arrayit microarray tests conveniently use a few drops of patient blood collected on a blood card to assist doctors in identifying and treating food intolerance, allergy and asthma, and pipeline indications for more serious conditions such as ovarian cancer and Parkinson’s Disease. Doctors can use allergy test results as quantitative tools to inform decisions regarding allergy medicines, immunotherapy, food elimination and lifestyle changes.
Arrayit CEO Rene Schena states, “We are pleased to announce allergy testing contracts with a medical clinics consortium comprising a remarkable breadth and depth of medical specialties and focus areas. Arrayit’s accurate and non-invasive allergy testing services can provide a healthcare cornerstone by empowering physicians to better treat and manage allergy and asthma and mitigate the acute and chronic consequences of these conditions.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
CONTACT: CONTACT Public Relations Arrayit Corporation Tel: 408-744-1331 Email: firstname.lastname@example.org Web: www.arrayit.com